Literature DB >> 24936720

Evaluation of renal mass biopsy risk stratification algorithm for robotic partial nephrectomy--could a biopsy have guided management?

Haider Rahbar1, Sam Bhayani2, Michael Stifelman3, Jihad Kaouk4, Mohamad Allaf5, Susan Marshall3, Homayoun Zargar4, Mark W Ball5, Jeffrey Larson2, Craig Rogers6.   

Abstract

PURPOSE: We evaluated a published biopsy directed small renal mass management algorithm using a large cohort of patients who underwent robotic partial nephrectomy for tumors 4 cm or smaller.
MATERIALS AND METHODS: A simplified algorithm of biopsy directed small renal mass management previously reported using risk stratified biopsies was applied to 1,175 robotic partial nephrectomy cases from 5 academic centers. A theoretical assumption was made of perfect biopsies that were feasible for all patients and had 100% concordance to final pathology. Pathology risk groups were benign, favorable, unfavorable and intermediate. The algorithm assigned favorable or intermediate tumors smaller than 2 cm to active surveillance and unfavorable or intermediate 2 to 4 cm tumors to treatment. Higher surgical risk patients were defined as ASA® 3 or greater and age 70 years or older.
RESULTS: Patients were assigned to the pathology risk groups of benign (23%), favorable (13%), intermediate (51%) and unfavorable (12%). Patients were also assigned to the management groups of benign pathology (275, 23%), active surveillance (336, 29%) and treatment (564, 48%). Most of the 611 (52%) patients in the benign or active surveillance groups were low surgical risk and had safe treatment (2.6% high grade complications). A biopsy may not have been feasible or accurate in some tumors that were anterior (378, 32%), hilar (93, 7.9%) or less than 2 cm (379, 32%). Of 129 (11%) high surgical risk patients the biopsy algorithm assigned 70 (54%) to benign or active surveillance groups.
CONCLUSIONS: The theoretical application of a biopsy driven, risk stratified small renal mass management algorithm to a large robotic partial nephrectomy database suggests that about half of the patients might have avoided surgery. Despite the obvious limitations of a theoretical assumption of all patients receiving a perfect biopsy, the data support the emerging role of renal mass biopsies to guide management, particularly in high surgical risk patients.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biopsy; carcinoma; kidney neoplasms; renal cell

Mesh:

Year:  2014        PMID: 24936720     DOI: 10.1016/j.juro.2014.06.028

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Association of Prevalence of Benign Pathologic Findings After Partial Nephrectomy With Preoperative Imaging Patterns in the United States From 2007 to 2014.

Authors:  Jae Heon Kim; Shufeng Li; Yash Khandwala; Kyung Jin Chung; Hyung Keun Park; Benjamin I Chung
Journal:  JAMA Surg       Date:  2019-03-01       Impact factor: 14.766

2.  Kidney cancer: Routine small renal mass needle biopsy should be adopted.

Authors:  Michael A S Jewett; Antonio Finelli
Journal:  Nat Rev Urol       Date:  2014-08-26       Impact factor: 14.432

3.  Partial vs Radical Nephrectomy for T1-T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes.

Authors:  Julie Y An; Mark W Ball; Michael A Gorin; Jiwon J Hong; Michael H Johnson; Christian P Pavlovich; Mohamad E Allaf; Phillip M Pierorazio
Journal:  Urology       Date:  2016-11-23       Impact factor: 2.649

Review 4.  Epidemiology of the Small Renal Mass and the Treatment Disconnect Phenomenon.

Authors:  Robert M Turner; Todd M Morgan; Bruce L Jacobs
Journal:  Urol Clin North Am       Date:  2017-03-14       Impact factor: 2.241

Review 5.  Renal angiomyolipoma: preoperative identification of atypical fat-poor AML.

Authors:  Crystal Farrell; Sabrina L Noyes; Mouafak Tourojman; Brian R Lane
Journal:  Curr Urol Rep       Date:  2015-03       Impact factor: 3.092

Review 6.  Imaging considerations for thermal and radiotherapy ablation of primary and metastatic renal cell carcinoma.

Authors:  Mohammad Haroon; Paul Sathiadoss; Rebecca M Hibbert; Satheesh Krishna Jeyaraj; Christopher Lim; Nicola Schieda
Journal:  Abdom Radiol (NY)       Date:  2021-07-10

7.  Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention.

Authors:  Arun R Menon; Ahmed A Hussein; Kristopher M Attwood; Tashionna White; Gaybrielle James; Bo Xu; Michael Petroziello; Charles L Roche; Eric C Kauffman
Journal:  J Urol       Date:  2021-03-29       Impact factor: 7.600

8.  Diagnostic renal mass biopsy is associated with individual categories of PADUA and RENAL nephrometry scores: Analysis of diagnostic and concordance rates with surgical resection.

Authors:  Ricardo B Fonseca; Melissa M Straub Hogan; Meghan E Kapp; Frances Cate; Alice Coogan; Sandeep Arora; Jennifer Gordetsky; Woodson W Smelser; Peter E Clark; Justin Cates; Giovanna A Giannico
Journal:  Urol Oncol       Date:  2021-03-26       Impact factor: 2.954

Review 9.  Magnetic Resonance Imaging as a Biomarker for Renal Cell Carcinoma.

Authors:  Yan Wu; Young Suk Kwon; Mina Labib; David J Foran; Eric A Singer
Journal:  Dis Markers       Date:  2015-11-01       Impact factor: 3.434

Review 10.  Complications of renal interventions: a pictorial review of CT findings.

Authors:  Jean S Z Lee; Jonathan Hall; Tom Sutherland
Journal:  Insights Imaging       Date:  2021-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.